Summit Therapeutics Inc. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Summit Therapeutics Inc. (SMMT) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 119.11 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-23.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-07-23
- Summit Therapeutics Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 118.90M shares, a 67.39% increase year-over-year.
- Summit Therapeutics Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 71.03M shares, a 18.39% increase year-over-year.
- Summit Therapeutics Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 60.00M shares, a 128.92% increase year-over-year.
- Summit Therapeutics Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-03-31 was 26.21M shares, a 37.23% increase year-over-year.
- Summit Therapeutics Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 115.68M shares, a 57.10% increase from fiscal 2024.
- Summit Therapeutics Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 73.64M shares, a 24.01% increase from fiscal 2023.
- Summit Therapeutics Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 59.38M shares, a 132.62% increase from fiscal 2022.
- Summit Therapeutics Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 25.53M shares, a 28.79% increase from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 11 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | 119.11M shares 10-Q · filed 2026-07-23 | ||||||
| 2026-03-31 | 118.90M shares 10-Q · filed 2026-04-30 | ||||||
| 2025-12-31 | 115.68M shares 10-K · filed 2026-02-23 | ||||||
| 2025-09-30 | 114.16M shares 10-Q · filed 2025-10-20 | ||||||
| 2025-06-30 | 114.57M shares 10-Q · filed 2026-07-23 | ||||||
| 2025-03-31 | 71.03M shares 10-Q · filed 2026-04-30 | ||||||
| 2024-12-31 | 73.64M shares 10-K · filed 2026-02-23 | ||||||
| 2024-09-30 | 73.61M shares 10-Q · filed 2025-10-20 | ||||||
| 2024-06-30 | 64.55M shares 10-Q · filed 2025-08-11 | ||||||
| 2024-03-31 | 60.00M shares 10-Q · filed 2025-05-01 | ||||||
| 2023-12-31 | 59.38M shares 10-K · filed 2026-02-23 | ||||||
| 2023-09-30 | 26.62M shares 10-Q · filed 2024-10-30 | ||||||
| 2023-06-30 | 26.33M shares 10-Q · filed 2024-08-06 | ||||||
| 2023-03-31 | 26.21M shares 10-Q · filed 2024-05-01 | ||||||
| 2022-12-31 | 25.53M shares 10-K · filed 2025-02-24 | ||||||
| 2022-09-30 | 25.39M shares 10-Q · filed 2023-11-07 | ||||||
| 2022-06-30 | 23.07M shares 10-Q · filed 2023-08-09 | ||||||
| 2022-03-31 | 19.10M shares 10-Q · filed 2023-05-11 | ||||||
| 2021-12-31 | 19.82M shares 10-K · filed 2023-03-09 | ||||||
| 2021-09-30 | 18.68M shares 10-Q · filed 2022-11-09 | ||||||
| 2021-06-30 | 11.05M shares 10-Q · filed 2022-08-11 | 12.75M shares 10-Q · filed 2021-08-12 | |||||
| 2021-03-31 | 11.36M shares 10-Q · filed 2022-05-11 | ||||||
| 2020-12-31 | 9.52M shares 10-K/A · filed 2022-12-21 | 9.52M shares 10-K · filed 2021-03-31 | |||||
| 2020-09-30 | 11.97M shares 10-Q · filed 2021-11-15 | ||||||
| 2020-06-30 | 10.88M shares 10-Q · filed 2021-08-12 | ||||||
| 2020-03-31 | 12.65M shares 10-Q · filed 2021-05-17 | ||||||
| 2019-12-31 | 13.40M shares 10-K · filed 2021-03-31 | ||||||
| 2019-09-30 | 4.13M shares 10-Q · filed 2020-11-16 | ||||||
| 2019-06-30 | 4.21M shares 8-K · filed 2020-09-29 | ||||||
| 2019-01-31 | 1.72M shares 10-K · filed 2021-03-31 | 1.62M shares 8-K · filed 2020-09-29 | |||||
| 2018-01-31 | 1.72M shares 8-K · filed 2020-09-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |